Gilead Sciences

GILD

157.3702.49% ( +3.830 )

Closed: Oct 15, 16:00:00 (EDT)

Current ValuationThe current P/E ratio is -58.76, below the reasonable range, cheaper than 99.87% of the time in the past 3 years, and the industry ranks 543/604, the industry Median -1.89.

-58.76xP/E

Stock price$153.54Earnings per share$-2.61

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

020406080

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
GILDUSGilead Sciences	-58.76x	150.48%	$190.38B
MRNAUSModerna	-28.67x	15.45%	$90.35B
CSLLYUSCSL Limited	-23.97x	--	$61.82B
NTRAUSNatera	-295.83x	6.85%	$56.90B
RVMDUSRevolution Medicines	-23.46x	62.09%	$41.48B
ROIVUSRoivant Sciences	-91.21x	146.49%	$24.28B
BNTXUSBioNTech SE	-11.39x	19.07%	$22.27B
INSMUSInsmed	-24.40x	74.51%	$21.36B
BBIOUSBridgebio Pharma	-18.35x	28.67%	$12.70B
SMMTUSSummit Therapeutics	-14.10x	20.67%	$12.07B
PCVXUSVaxcyte	-9.99x	48.18%	$10.63B
MDGLUSMadrigal Pharma	-32.69x	51.32%	$10.63B
IBRXUSImmunityBio	-10.58x	153.51%	$10.50B
TWSTUSTwist Bioscience	-71.34x	28.71%	$9.75B
KYMRUSKymera Therapeutics	-29.65x	5.24%	$8.88B
CYTKUSCytokinetics	-9.86x	6.68%	$8.82B
ARWRUSArrowHead Pharma	-25.77x	35,923.70%	$8.25B
ABVXUSAbivax SA	-16.49x	22.49%	$7.67B
IONSUSIonis Pharma	-12.56x	50.43%	$7.10B
SYREUSSpyre Therapeutics	-46.16x	45.67%	$6.93B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.